The Heart Condition That Had Zero Dedicated Treatments (Until Now)

This isn't a startup swinging for the fences on a hunch. JenaValve has been developing this technology for over two decades. The company traces its origins to 1995, when professors at Friedrich Schiller University in Germany patented the first percutaneous self-expanding aortic stent. JenaValve was formally established in 2005 and received CE Mark approval in Europe in 2021.

The U.S. approval took longer because the FDA required a dedicated pivotal trial. And that trial delivered.

The Numbers That Got the FDA to Say Yes

The ALIGN-AR Pivotal Trial enrolled 500 patients with symptomatic severe AR who were at high or greater risk for open-heart surgery. It was a single-arm study (no comparison group; patients were measured against prespecified performance benchmarks), and the results cleared every bar the FDA set.

The 30-day safety composite came in at 24%, comfortably below the 40.5% threshold. One-year all-cause mortality hit 7.7%, beating the 25% benchmark by a wide margin. Perhaps most impressively, technical success (meaning the device deployed correctly and worked as intended) reached 94.9%. Compare that to the 61-81% device success range seen with off-label TAVR devices in AR, and you start to understand why cardiologists are excited.

Two-year follow-up data from the core group showed sustained improvements in heart function, quality of life, and blood flow measurements. These results were published in The Lancet and presented at major cardiology conferences, including PCR London Valves in November 2025.

"The Answer Is Yes"

Martin B. Leon, MD, a professor of medicine at Columbia University, put it plainly: "We now have the answer to a question that the cardiology community had struggled with: can we safely and effectively treat patients with severe aortic regurgitation with a transcatheter device? The answer is yes."

That quote matters because Leon isn't some obscure researcher. He's the director of the Center for Interventional Vascular Therapy at Columbia and NewYork-Presbyterian, one of the most influential voices in interventional cardiology. When he calls something a "landmark achievement" and a "new standard of care," the field listens.

JenaValve CEO John Kilcoyne called the approval a "defining moment" and announced plans for an immediate U.S. launch, starting at the hospitals that participated in the ALIGN-AR trial before expanding to additional centers.

The Elephant That Almost Blocked the Room

There's an interesting wrinkle in JenaValve's story. In July 2024, Edwards Lifesciences (the biggest player in TAVR) agreed to acquire JenaValve, presumably to bolster its AR portfolio. But the FTC stepped in and blocked the deal in January 2026, citing antitrust concerns about patient access to heart treatments.

So JenaValve is launching this device as an independent company, competing against the giants that dominate the $7+ billion TAVR market. That's a David-and-Goliath setup if there ever was one, though David in this case has the only FDA-approved slingshot for the job.

What This Means for Patients (and the Market)

Aortic regurgitation isn't rare. AR affects roughly 0.5% of U.S. adults, and that number climbs sharply with age. Many cases go undiagnosed because symptoms develop gradually. By the time patients need intervention, they're often elderly and frail; exactly the population that struggles most with open-heart surgery.

Until now, those patients had two options: manage symptoms with medication (which doesn't fix the underlying problem) or undergo surgical valve replacement (invasive, risky, and not everyone qualifies). The Trilogy system creates a third path, one that's minimally invasive and purpose-built for the condition.

The broader TAVR market is watching closely. North America already accounts for about 43% of global TAVR revenue, and the addition of an entirely new indication could meaningfully expand the addressable patient population. For JenaValve, the question isn't whether the device works. The trial answered that. The question is whether an independent company can build the commercial infrastructure to reach the patients who need it.

For cardiologists and their patients, though, the calculus is simpler. A condition that had zero dedicated transcatheter treatments now has one. That's the kind of milestone that doesn't need spin to feel significant.